Keck Medicine of USC has launched its COVID Recovery Clinic, a multidisciplinary program led by a core team of clinicians specializing in primary care, pulmonology and physical therapy.
News | Coronavirus (COVID-19)
Keck Medicine of USC Launches COVID Recovery Clinic to Treat Patients with Long COVID-19
April 4, 2022 – Keck Medicine of USC has launched its COVID Recovery Clinic, a multidisciplinary program led by a core ...
Home April 04, 2022
Home
Staying well-hydrated may be associated with a reduced risk for developing heart failure, according to researchers at the National Institutes of Health.
News | Heart Failure
Good Hydration May Reduce Long-term Risks for Heart Failure
April 4, 2022 – Staying well-hydrated may be associated with a reduced risk for developing heart failure, according to ...
Home April 04, 2022
Home
Observational research has suggested that light alcohol consumption may provide heart-related health benefits, but in a large study published in JAMA Network Open, alcohol intake at all levels was linked with higher risks of cardiovascular disease.
News | Heart Failure
Large Study Challenges Theory that Light Alcohol Consumption Benefits Heart Health
April 4, 2022 – Observational research has suggested that light alcohol consumption may provide heart-related health ...
Home April 04, 2022
Home
But scientists at the Medical College of Georgia and Georgia State University also say that the chronic high-salt diet most Americans consume can turn this system against us, resulting in hyperactivity of these neurons, continuing production of this hormone vasopressin, constriction of blood vessels and increasing our risk for common cardiometabolic diseases like high blood pressure and heart disease.
News | Heart Failure
New Clues About How A High-Salt Diet Contributes to Cardiometabolic Diseases Found Deep in the Brain
April 4, 2022 – Deep in the brain a group of large neurons produce a hormone which prompts our bodies to hold onto more ...
Home April 04, 2022
Home
Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the first patient has been enrolled in the quadruple-blinded sham-controlled AIM HIGHer IDE clinical study (Assessment of Implantable CCM in the Heart Failure Group with Higher Ejection Fraction) evaluating CCM therapy for patients who have left ventricular ejection fraction ranging between 40% and 60% inclusive. The study will be conducted across approximately 150 cente
News | Heart Failure
Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer Study

April 4, 2022 – Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart ...

Home April 04, 2022
Home
Nexletol logo
News | ACC
Esperion Announces Two NEXLETOL Data Presentations at ACC.22
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
Significant VHD is commonly encountered in practice, more commonly with advancing age, among women, and identified more frequently in centers offering percutaneous mitral therapies.
News | ACC
egnite, Inc. Announces Data from the Largest Contemporary Analysis of Valvular Heart Disease Prevalence in the US

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C.
News | ACC
ACC22: Interim Findings Show Promise in Decreasing Shortness of Breath From Hypertrophic Cardiomyopathy

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today presented detailed results from its phase 1 APOLLO trial
News | Heart Failure
Silence Therapeutics Announces Detailed Results from SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at ACC22

April 3, 2022 — Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ...

Home April 03, 2022
Home
Aidoc, a leading provider of healthcare AI solutions, announced that it received FDA 510(k) clearance for its triage and notification of pneumothorax on X-ray exams.
News | Artificial Intelligence
Aidoc Expands AI Service to X-ray, Receiving FDA 510(k) Clearance for Pneumothorax

April 2, 2022 — Aidoc, a leading provider of healthcare AI solutions, announced that it received FDA 510(k) clearance ...

Home April 02, 2022
Home
Royal Philips, a global leader in health technology, today announced the launch of Ultrasound Workspace [OLK1] at the American College of Cardiology’s Annual Scientific Session & Expo (ACC 2022).
News | Cardiovascular Ultrasound
Philips Launches Ultrasound Workspace at ACC 2022

April 2, 2022 — Royal Philips, a global leader in health technology, today announced the launch of Ultrasound Workspace ...

Home April 02, 2022
Home
New ACC/AHA/HFSA guideline redefines heart failure stages to focus on prevention, updates treatment options and emphasizes care coordination with a heart failure specialty team
News | Heart Failure
ACC, AHA, HFSA Issue Joint Heart Failure Guideline

April 1, 2022 — A new joint guideline published today from the American College of Cardiology, the American Heart ...

Home April 01, 2022
Home
Philips Ambient Experience with FlexVision display for pediatric patients
News | ACC
Philips Adds to its Cardiology Suite of Solutions at ACC 2022

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
The poster titled “Short term prediction of Atrial Fibrillation from ambulatory ECG using deep learning” presents results of a clinical study demonstrating that Cardiologs’ AI algorithm can predict the short-term risk of atrial fibrillation (AFib) based on single-lead Ambulatory electrocardiograms (ECGs) that show normal sinus rhythm.
News | Atrial Fibrillation
Cardiologs Announces Poster Presentation at ACC 2022

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
News | ACC
Aidoc Showcases Full Cardiovascular AI Care Coordination Suite at ACC.22
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now